pocketful logo
Hindustan Bio Sciences Ltd logo

Hindustan Bio Sciences Ltd

NSE: BSE: 532041

7.80

(-2.50%)

Thu, 26 Mar 2026, 05:29 pm

Hindustan Bio Sciences Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    7.60

  • Net Profit

    0.10

  • P/B

    7.93

  • Sector P/E

    39.30

  • P/E

    69.80

  • EV/EBITDA

    96.60

  • Debt/Equity (Industry)

    0.23

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    12.90

  • RONW (Industry)

    12.30

  • ROE

    4.88

  • ROCE

    2.18

  • Debt/Equity

    2.98

  • EPS (TTM)

    0.14

  • Dividend Yield

    0

  • Book Value

    0.84

  • Interest Cover

    0

Analysis

all

thumbs up icon

Pros

  • Hindustan Bio Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Hindustan Bio Sciences is profitable, therefore cash runway is not a concern.
  • Hindustan Bio Sciences is profitable, therefore cash runway is not a concern.
  • Interest payments on debt are well covered by earnings (EBIT is 195.2x coverage).
  • Low level of unsold assets.
thumbs up icon

Cons

  • Unable to evaluate Hindustan Bio Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Hindustan Bio Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Operating cash flow is negative therefore debt is not well covered.
  • Debt is not covered by short term assets, assets are 0.5x debt.
  • Hindustan Bio Sciences's long term commitments exceed its cash and other short term assets.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters12.1912.1912.1912.1912.19
FII00000
DII00000
Public87.8187.8187.8187.8187.81
Government00000

Read More

Technical Analysis

RSI

45.96

MACD

-0.02

50 DMA

7.46

200 DMA

7.68

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic12.6910.368.988.036.655.703.37
Fibonacci10.369.478.928.037.146.595.70
Camarilla8.258.047.828.037.407.186.97

Pivots Level: Classic

R3

+4.66

12.69

R2

+2.33

10.36

R1

+0.96

8.98

8.03
8.03
Pivot Point
LTP: 7.41

S1

-1.37

6.65

S2

-2.33

5.70

S3

-4.66

3.37

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    7.60

  • 20-EMA

    7.66

  • 30-EMA

    7.62

  • 50-EMA

    7.46

  • 100-EMA

    7.32

  • 200-EMA

    7.56

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
31 Jan 2026board-meetingsQuarterly Results
31 Oct 2025board-meetingsQuarterly Results
31 Jul 2025agm
31 Jul 2024agm
04 Dec 2023egm
31 Jul 2023agm
07 Sept 2022agm
18 Jun 2021agm

Read More

Peer Comparison

Hindustan Bio Sciences Ltd logo

Hindustan Bio Sciences Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Read More

Hindustan Bio Sciences Ltd About

Hindustan Bio Sciences is engaged in the manufacturing and sale of pharmaceutical products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1991

Headquarters

CEO

J.V.R. Mohan Raju

Employees

Contact

Website icon

Website

http://www.hindustanbiosciences.in

Email icon

Email

mohan.hindustanbio@gmail.com, pharma.hindustanbio@

Phone icon

Phone

91-40-23555161/23555181

Location icon

Location

H No 8-2-269/S PlotNo 31 RdNo2, Sagar Co-Op Hous Banjara Hills, Hyderabad, Telangana, 500034

Read More

Hindustan Bio Sciences Ltd Company History

YearHistory
2001
  • The Company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd for dematerialisation.
2004
  • Hindustan Bio bagged GEAC nod for recombinant human erythropoietin.
2005
  • Hindustan Bio Sciences Ltd received an order for Antiretroviral drug for a value of Rs 269.30 million from China.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
RATNESH YOGESH BHONSLESell535016.5727 Oct 2025
VANDANA YOGESH BHOSALESell1065187.2923 Oct 2025
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDBuy790213.4723 Oct 2024
VIVEK KANDABuy5250013.4623 Oct 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDSell8400013.4623 Oct 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDBuy5360111.0917 Oct 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDBuy6500013.7820 Oct 2023
JAI VINAYAK SECURITIESBuy5368012.4818 Oct 2023
JAI VINAYAK SECURITIESSell5368012.3718 Oct 2023
BP EQUITIES PVT. LTD.Sell6783311.0117 Oct 2023

Read More

Hindustan Bio Sciences Ltd News

Hindustan Bio Sciences Q3FY26 Profit Jumps

Hindustan Bio Sciences Limited reported a profit of ₹8.20 lakhs for Q3FY26 ended December 31, 2025, marking a strong turnaround from losses in previous quarters.

31 Jan 2026

co actions results

Hindustan Bio Sciences Reports Share Acquisition

Bosco Armando Menezes & Emily Bosco Menezes acquire 15,000 shares through open market purchase, increasing combined holding to 5.12% in Hindustan Bio Sciences Limited.

23 Jan 2026

co actions results

Hindustan Biosciences Reports Mixed Quarterly Performance with Revenue Decline

Hindustan Biosciences Limited reported a loss of Rs 5.85 lakhs for the quarter ended September 30, 2025, compared to a profit of Rs 1.40 lakhs in the previous quarter. Revenue from operations dropped to Rs 32.19 lakhs from Rs 42.54 lakhs in the comparable period. For the half-year period, the company posted a loss of Rs 4.45 lakhs. Total expenses decreased to Rs 6.71 lakhs from Rs 32.41 lakhs in the previous quarter. The company's cash and cash equivalents stood at Rs 1.63 lakhs. Employee benefit expenses were Rs 4.96 lakhs for the quarter. The Board of Directors approved these unaudited standalone financial results in their meeting held on October 31, 2025.

31 Oct 2025

earnings

Hindustan Bio Sciences Reports Quarterly Financial Results for June 2025

Hindustan Bio Sciences Ltd published its unaudited financial results for the quarter ended June 30, 2025, in compliance with regulatory requirements. The company reported total income of ₹32.19 lakhs compared to ₹41.11 lakhs in the same quarter last year. Net profit after tax stood at ₹1.40 lakhs versus ₹8.18 lakhs in the previous year quarter. The company operates in the pharmaceutical trading segment. Results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 31, 2025, with statutory auditors expressing an unmodified audit opinion.

04 Aug 2025

earnings

Hindustan Biosciences Reports Q1 Results, Appoints New Company Secretary

Hindustan Biosciences Ltd. reported quarterly results showing revenue from operations of Rs 32.19 lakhs and profit of Rs 1.40 lakhs for the quarter ended June 30, 2025. The company announced the resignation of Company Secretary Devanshu Ravinder Dange due to personal reasons, effective July 31, 2025. Shailendra Vyas has been appointed as the new Company Secretary, Key Managerial Personnel and Compliance Officer from August 1, 2025. The board approved the notice for the 33rd Annual General Meeting scheduled for September and adopted the Secretarial Audit Report. VBSS Prasad was appointed as scrutinizer for e-voting at the upcoming AGM.

31 Jul 2025

corporate action

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800